5-Amino-1MQ

Not FDA-approved. Commonly discussed research dosages range from 50-150 mg/day orally, often taken as 50 mg one to three times daily with meals. Typical cycles are 4-12 weeks. Human clinical data is very limited; most evidence is from animal studies.

Selectively inhibits nicotinamide N-methyltransferase, preventing the methylation of nicotinamide (NAM) and depletion of S-adenosylmethionine (SAM). This preserves intracellular NAD+ levels by preventing the NNMT-mediated 'methyl sink' that drains energy precursors.

By blocking NNMT, intracellular NAD+ concentrations increase, enhancing mitochondrial function and shifting cellular energy metabolism toward fat oxidation over fat storage.

Reduces intracellular 1-methylnicotinamide (1-MNA) and suppresses de novo lipogenesis in adipocytes, leading to reduced fat cell size without changes in caloric intake.

Animal studies show reductions in fat cell size by 30-40% and notable reduction in visceral fat without changes in calorie intake.

By preserving NAD+ levels, mitochondrial function is enhanced, potentially increasing basal metabolic rate and energy expenditure.

NNMT inhibition has been associated with improved lipid profiles in preclinical models, including reduced total cholesterol.

Unlike caloric restriction alone, NNMT inhibition may preferentially target adipose tissue while preserving lean mass, though human data is limited.

Emerging evidences suggest that autophagy, a key cellular process responsible for degrading and recy...

Brain research · Rishika Dhapola, Sneha Kumari, Prajjwal Sharma, Balachandar ...

Inhibitors of NAD

International journal of molecular sciences · Moustafa S Ghanem, Irene Caffa, Fiammetta Monacelli, Alessio...

Human neurodegenerative proteinopathies are disorders associated with abnormal protein depositions i...

Human molecular genetics · Meredith Pinkerton, Andrea Ruetenik, Viktoriia Bazylianska, ...

SARM1 is an inducible TIR-domain NAD

Cell reports · Tong Wu, Jian Zhu, Amy Strickland, Kwang Woo Ko, Yo Sasaki

Interleukin-8 drives CD38 to form NAADP from NADP

FASEB journal : official publication of the Federation of American Societies for Experimental Biology · Tae-Sik Nam, Dae-Ryoung Park, So-Young Rah, Tae-Gyu Woo, Hun...